ANTIGEN BINDING PROTEINS

Abstract

This application discloses antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.

Description

Claims

1. An isolated nucleic acid molecule which encodes an antigen binding protein which is capable of binding Lymphocyte Activating Gene 3 (LAG-3) and which comprises CDRL1 comprising SEQ ID NO: 1;CDRL2 comprising SEQ ID NO: 2;CDRL3 comprising SEQ ID NO: 3;CDRH1 comprising SEQ ID NO: 6;CDRH2 comprising SEQ ID NO: 7; andCDRH3 comprising SEQ ID NO: 8.

2. An isolated nucleic acid molecule according to claim 1, wherein the antigen binding protein encoded by the isolated nucleic acid molecule is a humanised antibody, wherein the humanised antibody comprises an IgG1 constant region.

3. An expression vector comprising a nucleic acid molecule according to claim 1.

4. An expression vector comprising a nucleic acid molecule according to claim 2.

5. A host cell comprising an expression vector according to claim 2.

6. A host cell comprising an expression vector according to claim 4.

7. A host cell comprising an expression vector according to claim 3, wherein FUT8 gene encoding alpha-1,6-fucosyltransferase has been inactivated in the host cell.

8. A host cell comprising an expression vector according to claim 4, wherein FUT8 gene encoding alpha-1,6-fucosyltransferase has been inactivated in the host cell.

9. A method of producing an antigen binding protein comprising a) culturing a host cell according to claim 5 and b) isolating the antigen binding protein.

10. A method of producing an antigen binding protein comprising a) culturing a host cell according to claim 7 and b) isolating the antigen binding protein.

11. A method of treatment of a human or animal subject comprising administering to the human or animal subject an antigen binding protein which is capable of binding Lymphocyte Activating Gene 3 (LAG-3) and which comprises CDRL1 comprising SEQ ID NO: 1;CDRL2 comprising SEQ ID NO: 2;CDRL3 comprising SEQ ID NO: 3;CDRH1 comprising SEQ ID NO: 6;CDRH2 comprising SEQ ID NO: 7; andCDRH3 comprising SEQ ID NO: 8.

12. A method of treatment according to claim 11, wherein the disease is associated with the involvement of pathogenic T cells in the human or animal subject.

13. A method of treatment according to claim 12, wherein the disease is an autoimmune disease or cancer.

14. A method of treatment according to claim 13, wherein the disease is an autoimmune disease and the autoimmune disease is selected from the group consisting of psoriasis, Crohn’s disease, rheumatoid arthritis, primary biliary cirrhosis, SLE, Sjogren’s syndrome, multiple sclerosis, ulcerative colitis, and autoimmune hepatitis.

15. A method of producing an antigen binding protein, comprising a) culturing a host cell according to claim 6, and b) isolating the antigen binding protein.

16. A method of producing an antigen binding protein comprising a) culturing a host cell according to claim 8, and b) isolating the antigen binding protein.